This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming.
ACS nano · 2026
RNA lipid nanoparticles stabilized during nebulization through excipient selection.
Nanoscale advances · 2025
Quantitative Visualization of Lipid Nanoparticle Fusion as a Function of Formulation and Process Parameters.
ACS nano · 2024
Latest funding
- $719,101
Development of Lipid nanoparticle RNA systems as novel therapeutics for endotoxemia resulting from severe bacterial infections
CIHR · 2024 · Co-investigator
- $577,574
Lipid Nanoparticle-messenger RNA (LNP-mRNA) as a versatile therapeutic platform for brain diseases
CIHR · 2024 · Co-investigator
- $975,376
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
CIHR · 2023 · Co-investigator
11 publications.
Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming.
Nair PG, Sheela UB, Vijayan VV, Howlett SE, Cullis P, Gujar S
RNA lipid nanoparticles stabilized during nebulization through excipient selection.
Slaughter KV, Isaacs-Bernal D, Donders EN, Wang S, Sabbah SG, Li XO, Dang M, Jackiw IM, Chan KYT, Cullis P, Shoichet MS
Quantitative Visualization of Lipid Nanoparticle Fusion as a Function of Formulation and Process Parameters.
Kamanzi A, Zhang Y, Gu Y, Liu F, Berti R, Wang B, Saadati F, Ciufolini MA, Kulkarni J, Cullis P, Leslie S
Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions.
Tafech B, Rokhforouz MR, Leung J, Sung MM, Lin PJ, Sin DD, Lauster D, Block S, Quon BS, Tam Y, Cullis P, Feng JJ, Hedtrich S
Value-based healthcare delivery through metabolomics-based personalized health platform.
Anwar MA, Barrera-Machuca AA, Calderon N, Wang W, Tausan D, Vayali T, Wishart D, Cullis P, Fraser R
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N, Sharma A, Chaturvedi A, Budida R, Scherr M, Kuchenbauer F, Lindner R, Noyan F, Sühs KW, Stangel M, Grote-Koska D, Brand K, Vornlocher HP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M
Systemic study of solvent-assisted active loading of gambogic acid into liposomes and its formulation optimization for improved delivery.
Tang WL, Tang WH, Szeitz A, Kulkarni J, Cullis P, Li SD
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.
Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, Manoharan M, Akinc A, Maier MA, Cullis P, Madden TD, Hope MJ
The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes.
de Jong SD, Basha G, Wilson KD, Kazem M, Cullis P, Jefferies W, Tam Y
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y
Development of Lipid nanoparticle RNA systems as novel therapeutics for endotoxemia resulting from severe bacterial infections
Principal investigators: Russell, James A
Keywords: Bacterial Infection; Entodoxin; High Density Lipoprotein; Lipid Nanoparticle; Low Density Lipoprotein; Mrna; Sepsis; Sirna
Lipid Nanoparticle-messenger RNA (LNP-mRNA) as a versatile therapeutic platform for brain diseases
Principal investigators: MacVicar, Brian A
Keywords: Brain Disease; Commercialization; Innovation; Life Sciences Business Creation; Lipid Nanoparticle; Nanomedicine; Preclinical-To-Clinical Translation; Rna Therapeutics
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
Principal investigators: Ross, Colin J; Blakney, Anna
Keywords: Animal Models; Base Editor; Gene Editing; Genetic Disease; Lipid Nanoparticle; Nanoparticle; Prime Editor
Elucidating mRNA-Lipid Nanoparticle Formulation Efficacy using Single-Particle Fluorescence Imaging
Principal investigators: Zhang, Yao
Keywords: Biophysics; Drug Delivery; Fluorescence; Imaging; Lipid Nanoparticle; Live Cell
Rational Design of Lipid Nanoparticle Systems for mRNA Delivery
Principal investigators: Cullis, Pieter R
Keywords: Bioengineering; Ionizable Lipids; Lipid Nanoparticles; Messenger Rna; Nucleic Acids
Rational Design of More Potent Lipid Nanoparticle mRNA Therapeutics
Principal investigators: Cheng, Miffy Hok Yan
Keywords: Lipid Nanoparticles; Mrna Delivery; Nanomedicine
Newly Optimized LNP Systems for Genetic drugs and Gene therapy in Neurological diseases
Principal investigators: Cullis, Pieter R; MacVicar, Brian A
Keywords: Animal Models; Brain; Drug Delivery; Gene Therapy; Genetic Drugs; Growth Factors; Lipid Nanoparticle; Mrna; Stroke
Developing RNA gene therapies to modulate circulating PAI-1 to alleviate thrombosis
Principal investigators: Ferraresso, Francesca
Keywords: Age-Associated Diseases; Crispr Gene Editing; Lipid Nanoparticles; Liver; Plasminogen Activator Inhibitor 1; Rna Gene Therapy; Thrombosis
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
Principal investigators: Ross, Colin J; Blakney, Anna
Keywords: Animal Models; Base Editor; Gene Editing; Genetic Disease; Lipid Nanoparticle; Nanoparticle; Prime Editor
Development of LNP/mRNA systems for direct transfection and generation of functional Chimeric Antigen Receptor (CAR) T-cells in-vivo for treatment of blood and other cancer cell types
Principal investigators: Cullis, Pieter R
Keywords: Cancer; Cart Therapy; Gene Therapy; Immunotherapy; Lipid Nanoparticles; Mrna
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biochemistry
- Biological Sciences
- Pathology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.